Denali Therapeutics Inc. (MUN:4DN)

Germany flag Germany · Delayed Price · Currency is EUR
17.44
0.00 (0.00%)
At close: Jan 22, 2026
-8.16%
Market Cap2.86B -5.0%
Revenue (ttm)n/a
Net Income-425.08M
EPS-2.48
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume58
Average Volume114
Open15.77
Previous Closen/a
Day's Range15.77 - 17.44
52-Week Range10.92 - 19.94
Betan/a
RSI59.78
Earnings DateFeb 27, 2026

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme r... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 517
Stock Exchange Munich Stock Exchange
Ticker Symbol 4DN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements